Literature DB >> 31919475

Combined TACE and sorafenib for HCC treatment.

Jordan Hindson1.   

Abstract

Entities:  

Year:  2020        PMID： 31919475     DOI： 10.1038/s41575-020-0265-0

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  1 in total

1.  Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.

Authors:  Masatoshi Kudo; Kazuomi Ueshima; Masafumi Ikeda; Takuji Torimura; Nobukazu Tanabe; Hiroshi Aikata; Namiki Izumi; Takahiro Yamasaki; Shunsuke Nojiri; Keisuke Hino; Hidetaka Tsumura; Teiji Kuzuya; Norio Isoda; Kohichiroh Yasui; Hajime Aino; Akio Ido; Naoto Kawabe; Kazuhiko Nakao; Yoshiyuki Wada; Osamu Yokosuka; Kenichi Yoshimura; Takuji Okusaka; Junji Furuse; Norihiro Kokudo; Kiwamu Okita; Philip James Johnson; Yasuaki Arai
Journal:  Gut       Date:  2019-12-04       Impact factor: 23.059
  1 in total
  2 in total

1.  The Prognostic Significance of miR-21 Expression among Surgically Resected Hepatocellular Carcinoma Patients: Evidence from a Meta-Analysis and Retrospective Cohort Study.

Authors:  Xujian Huang; Yongfu Xiong; Jialin Yang; Gang Yang; Jingdong Li
Journal:  Biomed Res Int       Date:  2020-12-21       Impact factor: 3.411

2.  Long Noncoding RNA FOXP4-AS1 Predicts Unfavourable Prognosis and Regulates Proliferation and Invasion in Hepatocellular Carcinoma.

Authors:  Jingchen Liang; Duo Wang; Guanhua Qiu; Xiaoqi Zhu; Junjie Liu; Hang Li; Pingping Guo
Journal:  Biomed Res Int       Date:  2021-02-01       Impact factor: 3.411
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.